UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 93

Sortiert nach

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

British journal of cancer, 2018-08, Vol.119 (5), p.538-545

2018

Volltextzugriff (PDF)

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

The lancet oncology, 2020-11, Vol.21 (11), p.1500-1512

2020

Volltextzugriff (PDF)

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

The lancet oncology, 2020-11, Vol.21 (11), p.1489-1499

2020

Volltextzugriff (PDF)

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Journal of hematology and oncology, 2016-10, Vol.9 (1), p.105-105, Article 105

2016

Volltextzugriff (PDF)

Clinical Characteristics, Pathology and Outcome of 237 Patients With Synovial Sarcoma: Single Center Experience

International journal of surgical pathology, 2022-06, Vol.30 (4), p.360-369

2022

Volltextzugriff (PDF)

Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors

BMC cancer, 2023-12, Vol.23 (1), p.1200-1200, Article 1200

2023

Volltextzugriff (PDF)

Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial

International journal of clinical oncology, 2021-09, Vol.26 (9), p.1611-1618

2021

Volltextzugriff (PDF)

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity

Frontiers in oncology, 2020-11, Vol.10, p.548300-548300

2020

Volltextzugriff (PDF)

A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): The final reports

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3510-3510

2021

Volltextzugriff (PDF)

Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis

BMC cancer, 2022-02, Vol.22 (1), p.212-212, Article 212

2022

Volltextzugriff (PDF)

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial

Journal of gastroenterology and hepatology, 2020-08, Vol.35 (8), p.1307-1316

2020

Volltextzugriff (PDF)

High‐grade myofibroblastic sarcoma of the pleura: A case report and literature review

Thoracic cancer, 2020-10, Vol.11 (10), p.3011-3014

2020

Volltextzugriff (PDF)

Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors

World journal of gastroenterology : WJG, 2014-11, Vol.20 (43), p.16252-16257

2014

Volltextzugriff (PDF)

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer

Cancer management and research, 2021-01, Vol.13, p.6199-6205

2021

Volltextzugriff (PDF)

Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study

Frontiers in oncology, 2022-11, Vol.12, p.852032-852032

2022

Volltextzugriff (PDF)

An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors

Chinese medical journal, 2013-05, Vol.126 (9), p.1642-1646

2013

Volltextzugriff (PDF)

A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer

BMC cancer, 2018-08, Vol.18 (1), p.803-803, Article 803

2018

Volltextzugriff (PDF)

Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma

Cancer management and research, 2021-01, Vol.13, p.9075-9083

2021

Volltextzugriff (PDF)

Prognostic factors of primary neuroendocrine breast cancer: A population‐based study

Cancer medicine (Malden, MA), 2022-07, Vol.11 (13), p.2533-2540

2022

Volltextzugriff (PDF)

The safety of an MRI simulation-guided boost after short-course preoperative radiotherapy for unresectable rectal cancer (SUNRISE): interim analysis of a randomized phase II trial

Radiation oncology (London, England), 2022-12, Vol.17 (1), p.214-9, Article 214

2022

Volltextzugriff (PDF)

Preoperative Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Phase II Randomized Study

Frontiers in oncology, 2022-04, Vol.12, p.870741-870741

2022

Volltextzugriff (PDF)

Clinicopathological Characteristics and Prognosis of Colorectal Cancer in Chinese Adolescent Patients

Chinese medical journal, 2015-12, Vol.128 (23), p.3149-3152

2015

Volltextzugriff (PDF)

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial

EClinicalMedicine, 2022-12, Vol.54, p.101667-101667, Article 101667

2022

Volltextzugriff (PDF)

Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy

Chinese journal of cancer research, 2021-08, Vol.33 (4), p.447-456

2021

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(92)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Clinical Characteristics, Pathology and Outcome of 237 Patients With Synovial Sarcoma: Single Center Experience

Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors

Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity

A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): The final reports

Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis

Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial

High‐grade myofibroblastic sarcoma of the pleura: A case report and literature review

Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer

Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study

An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors

A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer

Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma

Prognostic factors of primary neuroendocrine breast cancer: A population‐based study

The safety of an MRI simulation-guided boost after short-course preoperative radiotherapy for unresectable rectal cancer (SUNRISE): interim analysis of a randomized phase II trial

Preoperative Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Phase II Randomized Study

Clinicopathological Characteristics and Prognosis of Colorectal Cancer in Chinese Adolescent Patients

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial

Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy

Suchergebnisse filtern